BrainStorm Brings MS Data on Heels of ALS BLA Announcement

BrainStorm Cell Therapeutics has made headlines of late for NurOwn in ALS, but the Israel and New York-based biotech considers itself a platform company.

On Thursday, the company announced the publication of peer-reviewed data from a Phase II trial of NurOwn in progressive multiple sclerosis Thursday showing “preliminary evidence of efficacy.”